Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

about

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q42323752

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@en

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@nl

type

Item

label

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@en

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@nl

prefLabel

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@en

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@nl

P1476

Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.

@en

P2093

Eishi Baba

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ariyama

http://www.w3.org/2001/XMLSchema#string

Hitoshi Kusaba

http://www.w3.org/2001/XMLSchema#string

Kenji Mitsugi

http://www.w3.org/2001/XMLSchema#string

Koichi Akashi

http://www.w3.org/2001/XMLSchema#string

Shuji Arita

http://www.w3.org/2001/XMLSchema#string

Shuji Nakano

http://www.w3.org/2001/XMLSchema#string

Taichi Isobe

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Shibata

http://www.w3.org/2001/XMLSchema#string

P2860

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.

Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.

Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.

Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management.

Primary adenocarcinoma of the jejunum and ileum: clinicopathological review of 25 cases.

Primary malignant tumors of the small intestine. A twenty-two year experience with thirty patients.

P304

423-426

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL_00000074

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230830821

http://www.w3.org/2001/XMLSchema#string

P698

22966319

http://www.w3.org/2001/XMLSchema#string

P932

3436425

http://www.w3.org/2001/XMLSchema#string